Calidi Biotherapeutics Inc
Research Calidi Biotherapeutics Inc (CLDI) on Bullrun: market cap USD 25.30M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCLDI
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 25.30M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 4.11M
- Free cash flow-USD 4.12M
Valuation Snapshot
latest market cap is USD 25.30M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 19.91M | -USD 21.41M | n/a | -5.95 | USD 5.82M | USD 690.00K | USD 3.76M |
| FY2024 | USD 0 | -USD 22.14M | -USD 19.71M | n/a | -35.7 | USD 9.60M | USD 3.82M | USD 1.53M |
| FY2023 | n/a | -USD 29.22M | n/a | n/a | -17.33 | USD 2.17M | USD 2.87M | -USD 8.24M |
| FY2022 | USD 45.00K | -USD 25.43M | n/a | n/a | 2.99 | USD 590.00K | USD 5.43M | -USD 50.44M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 25.30M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 8.44M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 23.87M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 53.54M | n/a | n/a | n/a |
| 2022 | 2022-09-29 | n/a | 375.9 | n/a | n/a |
| 2021 | 2021-12-31 | n/a | 981.0 | n/a | n/a |
About Calidi Biotherapeutics Inc
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Calidi Biotherapeutics Inc's market cap?
Calidi Biotherapeutics Inc's market capitalization is USD 25.30M.
What does Calidi Biotherapeutics Inc do?
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc.